| Schedule of segment information |
| | | | | | | | | | | | | | | Six Months Ended June 30, 2026 | | | Oncology/Immunology | | | | | | | | | | | Marketed | | | | Other | | | | | | | R&D | | Products | | Subtotal | | Ventures | | Unallocated | | Total | | | | (in US$’000) | Revenue from external customers | | 40,887 | | 121,434 | | 162,321 | | 115,966 | | — | | 278,287 | Cost of revenue | | — | | (40,350) | | (40,350) | | (111,808) | | — | | (152,158) | Research and development expenses | | (78,783) | | — | | (78,783) | | — | | — | | (78,783) | Selling expenses | | — | | (12,709) | | (12,709) | | (1,973) | | — | | (14,682) | Administrative expenses | | (16,910) | | (2,186) | | (19,096) | | (2,327) | | (10,372) | | (31,795) | Interest income | | 309 | | — | | 309 | | 32 | | 26,201 | | 26,542 | Interest expense | | (1,049) | | — | | (1,049) | | (210) | | (166) | | (1,425) | Equity in earnings of equity investees, net of tax | | 11 | | — | | 11 | | 3,787 | | — | | 3,798 | Income tax expense | | (337) | | (465) | | (802) | | (27) | | (380) | | (1,209) | Other segment items | | (1,531) | | (9,453) | | (10,984) | | 396 | | (2,059) | | (12,647) | Net (loss)/income attributable to the Company | | (57,403) | | 56,271 | | (1,132) | | 3,836 | | 13,224 | | 15,928 | Depreciation/amortization | | (4,849) | | (2,149) | | (6,998) | | (53) | | (21) | | (7,072) | Impairment (note) | | — | | (8,941) | | (8,941) | | — | | — | | (8,941) | Additions to non-current assets (other than financial instruments and deferred tax assets) | | 6,774 | | 6 | | 6,780 | | 242 | | 3 | | 7,025 |
Note: On March 9, 2026, Ipsen S.A. announced the voluntary withdrawal of tazemetostat globally and the Group discontinued all tazemetostat commercial and development activities. Accordingly, the Group has fully impaired the related intangible asset and was included in Other income, net in the condensed consolidated statements of operations. | | | | | | | | | | | | | | | Six Months Ended June 30, 2025 | | | Oncology/Immunology | | | | | | | | | | | Marketed | | | | Other | | | | | | | R&D | | Products | | Subtotal | | Ventures | | Unallocated | | Total | | | | (in US$’000) | Revenue from external customers | | 44,408 | | 99,039 | | 143,447 | | 134,230 | | — | | 277,677 | Cost of revenue | | — | | (38,223) | | (38,223) | | (129,354) | | — | | (167,577) | Research and development expenses | | (71,990) | | — | | (71,990) | | — | | — | | (71,990) | Selling expenses | | — | | (11,828) | | (11,828) | | (2,045) | | — | | (13,873) | Administrative expenses | | (14,599) | | (1,564) | | (16,163) | | (2,222) | | (9,366) | | (27,751) | Gain on divestment of an equity investee | | — | | — | | — | | — | | 477,456 | | 477,456 | Interest income | | 509 | | — | | 509 | | 57 | | 19,023 | | 19,589 | Interest expense | | (1,033) | | — | | (1,033) | | (257) | | (175) | | (1,465) | Equity in earnings of an equity investee, net of tax | | — | | — | | — | | 23,125 | | — | | 23,125 | Income tax expense | | (394) | | (67) | | (461) | | (481) | | (62,220) | | (63,162) | Other segment items | | (2,612) | | (74) | | (2,686) | | 928 | | 4,683 | | 2,925 | Net (loss)/income attributable to the Company | | (45,711) | | 47,283 | | 1,572 | | 23,981 | | 429,401 | | 454,954 | Depreciation/amortization | | (5,602) | | (422) | | (6,024) | | (51) | | (43) | | (6,118) | Additions to non-current assets (other than financial instruments and deferred tax assets) | | 5,649 | | 10,000 | | 15,649 | | 150 | | — | | 15,799 |
| | | | | | | | | | | | | | | June 30, 2026 | | | Oncology/Immunology | | | | | | | | | | | Marketed | | | | Other | | | | | | | R&D | | Products | | Subtotal | | Ventures | | Unallocated | | Total | | | | (in US$’000) | Total assets | | 182,720 | | 87,454 | | 270,174 | | 148,795 | | 1,317,458 | | 1,736,427 | Property, plant and equipment | | 93,382 | | — | | 93,382 | | 367 | | 39 | | 93,788 | Right-of-use assets | | 6,159 | | — | | 6,159 | | 726 | | 445 | | 7,330 | Leasehold land | | 11,313 | | — | | 11,313 | | — | | — | | 11,313 | Goodwill | | — | | — | | — | | 3,234 | | — | | 3,234 | Investment in equity investees | | 4,446 | | — | | 4,446 | | 6,574 | | — | | 11,020 |
| | | | | | | | | | | | | | | December 31, 2025 | | | Oncology/Immunology | | | | | | | | | | | Marketed | | | | Other | | | | | | | R&D | | Products | | Subtotal | | Ventures | | Unallocated | | Total | | | | (in US$’000) | Total assets | | 175,378 | | 91,353 | | 266,731 | | 117,359 | | 1,369,007 | | 1,753,097 | Property, plant and equipment | | 94,194 | | — | | 94,194 | | 370 | | 59 | | 94,623 | Right-of-use assets | | 1,451 | | — | | 1,451 | | 918 | | 658 | | 3,027 | Leasehold land | | 10,954 | | — | | 10,954 | | — | | — | | 10,954 | Intangible asset | | — | | 8,941 | | 8,941 | | — | | — | | 8,941 | Goodwill | | — | | — | | — | | 3,112 | | — | | 3,112 | Investment in equity investees | | 5,725 | | — | | 5,725 | | 5,140 | | — | | 10,865 |
|
| Schedule of geographic information |
| | | | | | | Six Months Ended June 30, | | | 2026 | | 2025 | | | | (in US$’000) | Revenue from external customers: | | | | | PRC | | 214,465 | | 205,120 | US and Others | | 63,822 | | 72,557 | | | 278,287 | | 277,677 |
| | | | | | | | | | | | | | | June 30, 2026 | | December 31, 2025 | | | PRC | | US and Others | | Total | | PRC | | US and Others | | Total | | | | (in US$’000) | Total assets | | 1,685,889 | | 50,538 | | 1,736,427 | | 1,705,638 | | 47,459 | | 1,753,097 | Property, plant and equipment | | 93,470 | | 318 | | 93,788 | | 94,183 | | 440 | | 94,623 | Right-of-use assets | | 6,880 | | 450 | | 7,330 | | 2,489 | | 538 | | 3,027 | Leasehold land | | 11,313 | | — | | 11,313 | | 10,954 | | — | | 10,954 | Intangible asset | | — | | — | | — | | 8,941 | | — | | 8,941 | Goodwill | | 3,234 | | — | | 3,234 | | 3,112 | | — | | 3,112 | Investment in equity investees | | 6,574 | | 4,446 | | 11,020 | | 5,140 | | 5,725 | | 10,865 |
|